Dallah Healthcare Company (TADAWUL:4004)
97.05
-3.05 (-3.05%)
Aug 13, 2026, 3:13 PM AST
Dallah Healthcare Company Ratios and Metrics
Market cap in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,848 | 12,700 | 14,607 | 16,782 | 13,320 | 6,759 | |
Market Cap Growth | -26.44% | -13.06% | -12.96% | 25.99% | 97.07% | 63.82% |
Enterprise Value | 14,022 | 16,186 | 16,725 | 18,797 | 15,237 | 8,308 |
Last Close Price | 97.70 | 123.81 | 145.68 | 164.82 | 140.60 | 70.36 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.49 | 23.60 | 31.00 | 46.60 | 48.53 | 26.14 |
Forward PE | 19.33 | 21.66 | 28.71 | 41.05 | 42.65 | 32.23 |
PS Ratio | 2.29 | 3.12 | 4.56 | 5.70 | 5.35 | 3.21 |
PB Ratio | 2.37 | 3.08 | 3.90 | 4.83 | 5.97 | 3.23 |
P/TBV Ratio | 2.87 | 3.76 | 4.47 | 5.59 | 7.46 | 4.04 |
P/FCF Ratio | - | 140.95 | 46.43 | 50.66 | 49.44 | 27.48 |
P/OCF Ratio | 23.57 | 22.87 | 21.54 | 26.82 | 30.13 | 18.70 |
PEG Ratio | 0.97 | 1.21 | 1.37 | 2.39 | 1.68 | 1.68 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.27 | 3.98 | 5.22 | 6.39 | 6.12 | 3.95 |
EV/EBITDA Ratio | 17.09 | 21.01 | 24.52 | 30.80 | 29.63 | 18.12 |
EV/EBIT Ratio | 24.11 | 27.23 | 29.49 | 37.12 | 36.43 | 22.99 |
EV/FCF Ratio | - | 179.63 | 53.16 | 56.74 | 56.55 | 33.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.02 | 0.96 | 0.54 | 0.57 | 0.89 | 0.90 |
Debt / EBITDA Ratio | 5.49 | 4.83 | 2.86 | 3.13 | 3.71 | 3.96 |
Debt / FCF Ratio | - | 43.66 | 6.43 | 5.96 | 7.34 | 7.68 |
Net Debt / Equity Ratio | 1.00 | 0.90 | 0.50 | 0.50 | 0.78 | 0.80 |
Net Debt / EBITDA Ratio | 5.75 | 4.83 | 2.72 | 2.85 | 3.38 | 3.67 |
Net Debt / FCF Ratio | -64.17 | 41.32 | 5.90 | 5.25 | 6.46 | 6.84 |
Asset Turnover | 0.47 | 0.52 | 0.50 | 0.53 | 0.52 | 0.48 |
Inventory Turnover | 7.41 | 8.68 | 8.61 | 8.02 | 6.87 | 7.07 |
Quick Ratio | 0.86 | 0.92 | 0.75 | 0.85 | 1.06 | 0.92 |
Current Ratio | 1.22 | 1.24 | 1.15 | 1.16 | 1.47 | 1.27 |
Return on Equity (ROE) | 10.31% | 13.74% | 13.44% | 13.51% | 13.65% | 13.40% |
Return on Assets (ROA) | 3.62% | 4.72% | 5.51% | 5.67% | 5.47% | 5.15% |
Return on Invested Capital (ROIC) | 6.26% | 8.70% | 10.11% | 10.62% | 9.69% | 9.48% |
Return on Capital Employed (ROCE) | 6.90% | 7.90% | 10.70% | 10.00% | 10.40% | 9.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.50% | 4.24% | 3.23% | 2.15% | 2.06% | 3.83% |
FCF Yield | -0.66% | 0.71% | 2.15% | 1.97% | 2.02% | 3.64% |
Dividend Yield | 2.06% | 1.62% | 1.37% | 0.91% | 1.78% | 2.13% |
Payout Ratio | 44.93% | 37.60% | 41.38% | 40.69% | 65.58% | 62.84% |
Buyback Yield / Dilution | -3.62% | -3.74% | -0.20% | -8.16% | - | -4.56% |
Total Shareholder Return | -1.56% | -2.12% | 1.18% | -7.25% | 1.78% | -2.43% |